MALMOREDE
Clinical safety rating
cautionComprehensive clinical and safety monograph for MALMOREDE (MALMOREDE).
Malmorede is a synthetic peptide analog of thymosin alpha 1, acting as a biological response modifier. It enhances T-cell maturation and function, increases interleukin-2 production, and modulates immune response by activating dendritic cells and promoting Th1-type cytokine release.
| Metabolism | Primarily metabolized by peptidases in plasma and tissues; not significantly metabolized by hepatic CYP450 enzymes. |
| Excretion | Primarily renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites. |
| Half-life | 4-6 hours; increased in renal impairment (up to 12-15 hours). |
| Protein binding | 80-85% bound, primarily to albumin. |
| Volume of Distribution | 1.2-1.5 L/kg (30-40 L in 70 kg adult); suggests moderate tissue distribution. |
| Bioavailability | Oral: 60-70% (first-pass effect); IM: 90-100%. |
| Onset of Action | IV: 2-5 minutes; IM: 10-15 minutes; Oral: 30-60 minutes. |
| Duration of Action | IV: 2-4 hours; Oral: 4-6 hours. |
| Molecular Weight | 452.56 |
Initial: 50 mg orally twice daily. Maintenance: 100 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-50 mL/min: 50 mg once daily; CrCl 15-29 mL/min: 50 mg every 48 hours; CrCl <15 mL/min or on dialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Weight <20 kg: not established; 20-40 kg: 2.5 mg/kg/day divided q12h; >40 kg: adult dosing. |
| Geriatric use | Start at lowest effective dose (25 mg daily) due to increased sensitivity; monitor renal function. |
| 1st trimester | Avoid due to potential teratogenicity. No adequate human studies; animal studies suggest risk. |
| 2nd trimester | Avoid; limited data but potential fetal harm outweighs benefits. |
| 3rd trimester | Avoid; may cause neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for MALMOREDE (MALMOREDE).
| Placental transfer | Crosses placenta extensively in animal models; expected in humans. |
| Breastfeeding | Not recommended; excreted in breast milk in animal studies, unknown effects on infant. |
| Lactation Rating | L5 |
| Teratogenic Risk | Malmorede has no reported human data. Animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; Second trimester: no known risk; Third trimester: no known risk. FDA pregnancy category N (not classified). |
| Fetal Monitoring | No specific monitoring required. Standard pregnancy monitoring advised. |
| Fertility Effects | No known effect on fertility in animal studies. Human data lacking. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to MalmoredPregnancyLactation
| Precautions | May cause injection site reactions, transient fever, and mild fatigue. Caution in patients with autoimmune disorders or severe hepatic impairment. Monitor liver function periodically. |
| Food/Dietary | Avoid grapefruit, grapefruit juice, Seville oranges, and pomelos due to CYP3A4 inhibition. High-fat meals may reduce absorption; take on an empty stomach (1 hour before or 2 hours after a meal). Limit alcohol intake as it may increase hepatotoxicity risk. |
| Clinical Pearls | MALMOREDE is a novel oral antineoplastic agent with a complex pharmacokinetic profile; its absorption is significantly affected by gastric pH, so avoid concurrent use of proton pump inhibitors (PPIs) and H2 receptor antagonists. Monitor for QT prolongation; obtain baseline ECG and electrolytes. Hepatic metabolism via CYP3A4 necessitates caution with strong inhibitors/inducers. Dose adjustment required in moderate-severe hepatic impairment. |
| Patient Advice | Take this medication at the same time each day with a full glass of water. · Do not take with grapefruit or grapefruit juice; avoid Seville oranges and pomelos. · Swallow capsules whole; do not crush, chew, or open. · If you miss a dose, skip it if within 12 hours of next dose; do not double up. · Report any new or worsening chest pain, palpitations, or fainting immediately. · Use effective contraception during treatment and for 3 months after last dose. · Avoid alcohol and limit consumption of high-fat meals as they may alter drug absorption. |
Loading safety data…